ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China

Autor: Yi-Feng Chen, Chao-Yang Zhang, Wan-Hua Chen, Pei-Ling Xin, Ya-Yun Chen, Wenjie Cai, Qun-Xiong Pan, Congren Wang, Zhi-Shan Zhang
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Male
Oncology
Pathology
Esophageal Neoplasms
Epidemiology
medicine.medical_treatment
DNA Mutational Analysis
Cancer Treatment
Gene Expression
lcsh:Medicine
Medicine and Health Sciences
Medicine
lcsh:Science
Multidisciplinary
Cancer Risk Factors
Genomics
Middle Aged
Esophageal cancer
Prognosis
DNA-Binding Proteins
Cell Transformation
Neoplastic
Chemotherapy
Adjuvant
Carcinoma
Squamous Cell
Female
Esophageal Squamous Cell Carcinoma
Anatomy
Cancer Epidemiology
Research Article
medicine.drug
China
medicine.medical_specialty
Genotype
Cell Survival
Radiation Therapy
Single-nucleotide polymorphism
Gastroenterology and Hepatology
Polymorphism
Single Nucleotide
Esophagus
Genomic Medicine
Internal medicine
Genetics
Cancer Detection and Diagnosis
Carcinoma
Adjuvant therapy
Humans
Genetic Testing
Alleles
Aged
Neoplasm Staging
Clinical Genetics
Cisplatin
Chemotherapy
business.industry
lcsh:R
Biology and Life Sciences
Endonucleases
medicine.disease
Gastrointestinal Tract
Radiation therapy
Radiotherapy
Adjuvant
lcsh:Q
Lymph Nodes
Neoplasm Grading
ERCC1
business
Digestive System
Zdroj: PLoS ONE, Vol 9, Iss 9, p e106600 (2014)
PLoS ONE
ISSN: 1932-6203
Popis: Esophageal carcinoma is one of the world's deadliest cancers. Esophageal squamous cell carcinoma (ESCC) is more frequent than adenocarcenoma (AC) in China. Platinum-based chemotherapy with surgical resection is a common treatment approach for ESCC; however, the treatment response is uncertain. Evidence suggests polymorphisms in genes encoding excision repair cross-complementing group 1 (ERCC1), a protein involved in nuclear excision repair (NER), may help predict response to cisplatin and other platinum-based chemotherapeutics. Multiple ERCC1 single nucleotide polymorphisms (SNPs) have been associated with platinum chemotherapy response. Two common SNPs occur at the C8092A and C118T loci. Our study aimed to determine if 1) an association exists between ERCC1 tumor expression and patient survival, 2) whether adjuvant therapy influence on survival is related to histological ERCC1 presence in tumor cell nuclei, and 3) whether other clinicopathological characteristics in a cohort of patients following surgery for various stages of ESCC are associated with tumor ERCC1 expression. One hundred eight patients were included in the study, and tumor biopsy was collected for genotyping and immunohistochemical analysis of ERCC1. Sixty-seven patients (62%) received no adjuvant therapy, and the rest had either platinum-based chemotherapy (28.5%), radiotherapy (6.5%) or both treatments (2.8%). Log-rank analysis revealed no significant connection between tumor ERCC1 expression (P = 0.12) or adjuvant therapy (P = 0.56) on patient survival. Also, non-parametric Mann-Whitney analysis showed no significant link between tumor size or nodus tumor formation and ERCC1 presence in patients in the study. Interestingly, C8092A SNP showed significant association with patient survival (P = 0.01), with patients homozygous for the mutant allele showing the most significantly reduced survival (P = 0.04) compared to those homozygous for the dominant allele (CC). Our results provide novel insight into the genotypic variation of patients from Quanzhou, Fujian province China.
Databáze: OpenAIRE
Externí odkaz: